Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2026.101383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Sieun Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea; Graduate Program in Innov…. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 216 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) is a key signaling component downstream of the B-cell receptor (BCR) and plays an essential role in the survival and proliferation of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM). BTK inhibitors (BTKi) have demonstrated substantial clinical benefit and are now widely incorporated into frontline treatment strategies. However, the long-term effectiveness of BTKi is frequently limited by the emergence of both intrinsic and acquired resistance. BTKi resistance reflects a dynamic process of cellular adaptation rather than a single dominant mechanism. Malignant B cells maintain viability under BTK inhibition through multiple, interconnected alterations, including changes in BTK structure or function, reprogramming of proximal BCR signaling, activation of alternative survival pathways, tumor microenvironment-mediated immune modulation, and metabolic and epigenetic remodeling. In this review, we summarize recent advances in BTK-targeted therapeutics and present a mechanistic framework for understanding BTKi resistance as an adaptive and context-dependent process. We discuss emerging resistance mechanisms that extend beyond canonical signaling pathways and review therapeutic strategies aimed at addressing these adaptive responses, including non-covalent BTK inhibitors, BTK degraders, and rational combination regimens. This perspective highlights translational strategies to improve the depth and durability of responses to BTK-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea; Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul 03760, R…
- College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10021, USA; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10021, USA. Electronic addre…
Förderung
- National Research Foundation of Korea
Zitieren
APA
Yang, S., Oh, J., Hwang, S. Y., Paik, J., & Hwang, I. (2026). Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101383
Vancouver
Yang S, Oh J, Hwang SY, Paik J, Hwang I. Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101383
BibTeX
@article{Yang2026,
author = {Yang, Sieun and Oh, Jihye and Hwang, Soo-Yeon and Paik, Jihye and Hwang, Inah},
title = {Advances and resistance adaptation in BTK-targeted therapy for B-cell malignancies},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2026.101383}
}
EUVIMED